FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Comparative efficacy of neoadjuvant short-course versus long-course radiotherapy-based regimens with or without immunotherapy for locally advanced pMMR rectal cancer: a systematic review and network meta-analysis. PMID 41826948 · BMC Med · 2026-Mar-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial. PMID 41826281 · Nat Commun · 2026-Mar-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial. PMID 41796601 · Lancet · 2026-Mar-14 The trial meets criteria for oncology, human, randomized, Phase III, drug intervention, and original result, but the primary efficacy endpoint is ORR, which is not a time-to-event endpoint as required. No time-to-event signal (Kaplan-Meier, HR, or time-to-event outcome) is identified in the abstract. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis. PMID 41765025 · Lancet · 2026-Mar-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Long-Term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial. PMID 41833909 · Int J Radiat Oncol Biol Phys · 2026-Mar-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Associations between tumor immune response and prognosis in node-negative breast cancer patients in the randomized DBCG HYPO trial. PMID 41826895 · BMC Cancer · 2026-Mar-13 The study is a randomized trial in oncology reporting a time-to-event endpoint, but it investigates radiotherapy fractionation schedules, not a drug-containing intervention. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. The primary focus is a biomarker/prognostic analysis, not the reporting of a drug's efficacy in a definitive trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone. PMID 41826282 · Pharmacogenomics J · 2026-Mar-13 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial. PMID 41824255 · J Patient Rep Outcomes · 2026-Mar-13 The study is part of a Phase III randomized trial (CARTITUDE-4) evaluating a drug intervention (ciltacabtagene autoleucel) in oncology (multiple myeloma). However, this specific abstract reports validation of a patient-reported outcome instrument (MySIm-Q) using trial data, not a time-to-event efficacy outcome (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. Therefore, it does not meet the time-to-event efficacy endpoint criterion for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized controlled phase III trial on continued or paused PD-1 pathway blockade for patients with advanced renal cell carcinoma (JCOG1905, STOP study): a study protocol. PMID 41324490 · Jpn J Clin Oncol · 2026-Mar-13 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer. PMID 41826123 · Eur Urol Focus · 2026-Mar-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The Efficacy and Safety of Enarodustat for the Treatment of Anemia in Hemodialysis-Dependent Chronic Kidney Disease Patients: A Phase 3, Multicenter, Randomized, Active-Comparator (Recombinant Human Erythropoietin), Open-Label Study - The ENARODIAL Study. PMID 41818346 · Am J Nephrol · 2026-Mar-12 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial. PMID 41816796 · Nutr Clin Pract · 2026-Mar-12 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia. PMID 41812193 · N Engl J Med · 2026-Mar-12 The record is a Phase 3 randomized oncology trial with a drug intervention and original results. However, the primary efficacy endpoint is a categorical proportion (odds ratio/risk ratio for absence of chemotherapy modifications), not a time-to-event outcome (OS, PFS, DFS, EFS, RFS, TTP, or any Kaplan-Meier/HR analysis). The deterministic review correctly flagged 'no_time_to_event_signal'. Therefore, it does not meet the time-to-event criterion for this adjudication. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial. PMID 41825810 · Int J Radiat Oncol Biol Phys · 2026-Mar-11 The report is a secondary analysis of a Phase III randomized trial, but it focuses on quality-of-life outcomes, not a time-to-event efficacy endpoint required for the cohort. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Who is missing from SGLT-2 inhibitor trials? Implications for drug safety and generalizability: a systematic review and meta-analysis. PMID 41784948 · Expert Opin Drug Saf · 2026-Mar-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study. PMID 41655462 · Eur J Cancer · 2026-Mar-11 This is a formal-result report from a Phase III randomized trial (ARASENS) but presents a secondary safety and dose-intensity analysis. It does not contain a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.) as required for inclusion in the Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study. PMID 41001841 · Sleep · 2026-Mar-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study. PMID 41875364 · Eur J Cardiothorac Surg · 2026-Mar-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg. PMID 41843763 · J Crohns Colitis · 2026-Mar-10 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Evolution of Anti-Vascular Endothelial Growth Factor Clinical Trial Design for Treating Neovascular Age-Related Macular Degeneration. PMID 41822409 · J Vitreoretin Dis · 2026-Mar-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Effect of Motivational Interviewing Based on the COM-B Model on Women's Cervical Cancer Health Beliefs and Participation in Screening: A Single-Blind Randomized Controlled Trial. PMID 41812047 · Cancer Nurs · 2026-Mar-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial. PMID 41807015 · BMJ Open Respir Res · 2026-Mar-10 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Sex as a moderator of the association between cardiorespiratory fitness and depressive symptoms in older adults. PMID 41691469 · J Gerontol B Psychol Sci Soc Sci · 2026-Mar-10 未发现恶性肿瘤人群证据。 |
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study. PMID 41538748 · J Clin Oncol · 2026-Mar-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Predictors of Skeletal-Related Events and Quality-of-Life Dimensions Among Patients With High-Risk Asymptomatic Bone Metastases With or Without Early Radiation Therapy: Secondary Analysis of a Multicenter Randomized Phase II Clinical Trial. PMID 41825136 · J Natl Compr Canc Netw · 2026-Mar-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms. PMID 41807028 · J Korean Med Sci · 2026-Mar-09 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical and radiographic outcomes of a novel posterior occlusal splint in adults with temporomandibular joint osteoarthritis: a retrospective case series. PMID 41803814 · BMC Oral Health · 2026-Mar-09 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Transthyretin amyloid depletion therapy: lessons from the phase 2 trial of coramitug. PMID 41801500 · Heart Fail Rev · 2026-Mar-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. PMID 41741368 · Oncologist · 2026-Mar-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term survival outcomes after biomarker-guided thromboprophylaxis in cancer: extended follow-up of the TARGET-TP randomised trial. PMID 41795841 · J Natl Cancer Inst · 2026-Mar-07 While the record meets many inclusion criteria (oncology, human, randomized, time-to-event, drug intervention, original result), the specific trial phase (Phase III/IIIb or Phase II/III) is not established in the provided metadata. The deterministic review note explicitly flags that phase evidence is unclear. Without confirmation of a definitive phase, eligibility cannot be set to true. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma. PMID 41794844 · Nat Commun · 2026-Mar-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Intravenous lidocaine reduces systemic inflammation but not myocardial injury following thoracic surgery for lung cancer: a randomized controlled trial. PMID 41794665 · BMC Anesthesiol · 2026-Mar-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. PMID 41794437 · Lancet · 2026-Mar-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| 5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial. PMID 41794436 · Lancet · 2026-Mar-07 The trial is a Phase 3 randomized trial in oncology (breast cancer) with a time-to-event primary endpoint (arm lymphoedema reported as HR), but the intervention is radiotherapy (radiation dose fractionation), not a drug. The criteria require a drug-containing intervention for eligibility. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care. PMID 41793559 · Breast Cancer Res Treat · 2026-Mar-07 The study is an observational comparative effectiveness analysis using a target trial emulation framework on real-world data, not a report of an original Phase III/IIIb or Phase II/III randomized controlled trial with a drug intervention. It does not meet the criteria for a primary or secondary report of a definitive randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prophylactic para-aortic irradiation vs pelvic radiotherapy in pelvic node-positive carcinoma cervix in the setting of concurrent chemoradiation: a phase II open-label multi centric randomized controlled trial (PRO-PARA). PMID 41792812 · Trials · 2026-Mar-07 The record describes a protocol for a Phase II/III randomized trial in cervical cancer with a drug (cisplatin) intervention. While it meets many inclusion criteria (oncology, human, randomized, phase 3, drug intervention), it is excluded because it is a protocol without reported results, and no time-to-event efficacy endpoint (e.g., OS, PFS) or survival analysis (Kaplan-Meier, HR) is described. The primary endpoint mentioned is 'demonstration of reduction in the risk of para-aortic recurrence,' but the abstract does not report any data, results, or confirm it as a time-to-event outcome suitable for KM digitization. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya. PMID 41564838 · Vaccine · 2026-Mar-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety, immunogenicity, and lot consistency of a 13-valent pneumococcal conjugate vaccine in Chinese children aged 2-5 years: A phase III study. PMID 41554243 · Vaccine · 2026-Mar-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Meningococcal quadrivalent ACYW-TT conjugated vaccine at 6-23 months: phase III study (US/Puerto Rico). PMID 41792337 · Pediatr Res · 2026-Mar-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Suzetrigine (a NaV1.8 inhibitor) versus placebo for acute postoperative pain: A systematic review and meta-analysis of randomized controlled trials. PMID 41790692 · Medicine (Baltimore) · 2026-Mar-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE). PMID 41786624 · Mod Rheumatol · 2026-Mar-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Kidney-Tonifying, Phlegm-Resolving, and Blood Stasis-Removing Therapy for Multiple Myeloma: Protocol for a Randomized Controlled Trial on Epigenetic and Immune Modulation. PMID 41813432 · JMIR Res Protoc · 2026-Mar-05 This is a protocol for a randomized trial in multiple myeloma, but it is not Phase III/IIIb or Phase II/III, and it lacks primary or secondary time-to-event efficacy endpoints (e.g., OS, PFS, DFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Thermal ablation versus hepatectomy for solitary colorectal liver metastases up to 5 cm: a multicenter target trial emulation on safety, efficacy, and cost-effectiveness. PMID 41787469 · BMC Med · 2026-Mar-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Desidustat's Efficacy and Safety in Non-Dialysis Chronic Kidney Disease Patients with Anemia. PMID 41785204 · Am J Nephrol · 2026-Mar-05 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety of extending dosing intervals of denosumab in adults with solid cancer and bone metastasis: a review. PMID 41785076 · Br J Nurs · 2026-Mar-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| AI-Driven Analysis of Cardiopulmonary Exercise Tests to Identify Gas Exchange and Ventilatory Thresholds. PMID 41784915 · Sports Med · 2026-Mar-05 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical evaluation of the efficacy and safety of nasturtium herb and horseradish root versus placebo in the continuous prophylaxis of recurrent uncomplicated cystitis: a double-blind randomised clinical trial. PMID 41782129 · BMC Complement Med Ther · 2026-Mar-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Finerenone in Type 1 Diabetes and Chronic Kidney Disease. PMID 41780000 · N Engl J Med · 2026-Mar-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial). PMID 40884070 · Eur Heart J · 2026-Mar-05 The trial is a randomized, double-blind, placebo-controlled study in advanced cancer patients, but the primary endpoint is a composite of functional/well-being measures, not a time-to-event efficacy endpoint. Mortality is mentioned as a secondary safety measure, not as a primary or key secondary time-to-event endpoint for efficacy analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Somapacitan in children born small for gestational age: a randomized controlled phase 3 trial. PMID 41782416 · Eur J Endocrinol · 2026-Mar-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |